Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stake Lifted by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC grew its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 894.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,381 shares of the biopharmaceutical company's stock after acquiring an additional 4,840 shares during the quarter. Tower Research Capital LLC TRC's holdings in Alnylam Pharmaceuticals were worth $1,266,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in ALNY. Jennison Associates LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $61,160,000. Strategic Financial Concepts LLC acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth approximately $41,529,000. Truist Financial Corp grew its stake in Alnylam Pharmaceuticals by 136.6% in the 4th quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company's stock worth $1,035,000 after acquiring an additional 2,539 shares during the period. Sumitomo Mitsui Trust Group Inc. raised its holdings in Alnylam Pharmaceuticals by 3.0% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company's stock valued at $67,464,000 after acquiring an additional 8,462 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in shares of Alnylam Pharmaceuticals by 13.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company's stock worth $4,687,000 after purchasing an additional 2,285 shares during the period. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Up 1.8 %

NASDAQ:ALNY traded up $4.68 on Tuesday, reaching $259.53. The stock had a trading volume of 222,602 shares, compared to its average volume of 852,630. The stock has a market cap of $33.76 billion, a P/E ratio of -119.60 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 12-month low of $143.81 and a 12-month high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The company has a 50-day moving average of $247.46 and a 200 day moving average of $255.63.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Activity

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the completion of the transaction, the chief executive officer now owns 81,526 shares of the company's stock, valued at $20,802,989.42. The trade was a 1.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CMO Pushkal Garg sold 1,561 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $398,320.37. Following the sale, the chief marketing officer now directly owns 13,537 shares in the company, valued at $3,454,236.29. This trade represents a 10.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 7,392 shares of company stock worth $1,875,627. 1.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts recently commented on ALNY shares. HC Wainwright reiterated a "buy" rating and issued a $500.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. Needham & Company LLC reiterated a "buy" rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 9th. Redburn Atlantic assumed coverage on shares of Alnylam Pharmaceuticals in a report on Monday, March 31st. They issued a "buy" rating and a $353.00 target price for the company. Wells Fargo & Company increased their price target on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a research note on Friday, March 21st. Finally, JPMorgan Chase & Co. raised shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their price objective for the company from $280.00 to $328.00 in a research note on Monday, March 24th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $315.58.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.